# AppliedXL

> AppliedXL is a New York-based event-detection company that builds machine-learning systems - it calls them editorial algorithms - to spot early signals in clinical trials, biotech, and financial data before they become news. Founded in 2020 by former Wall Street Journal computational journalists Francesco Marconi and Erin Riglin out of the Newlab Venture Studio, the company mines public databases like ClinicalTrials.gov to flag trial delays, enrollment shortfalls, and irregular status changes across more than 100 risk categories, feeding real-time intelligence to life-sciences executives and investors. Its work powers STAT Trials Pulse and appears on the Bloomberg Terminal.

- **Founded:** 2020
- **Headquarters:** Brooklyn, New York, United States
- **Founders:** Francesco Marconi (Co-Founder & CEO), Erin Riglin (Co-Founder & CTO)
- **Team size:** ~14 employees
- **Products:** Predictive Intelligence Platform, STAT Trials Pulse, Clinical Trial API & Data Feeds, Bloomberg Terminal Pharma News
- **Notable:** Signals and AI-powered pharma news distributed through the Bloomberg Terminal., Co-created STAT Trials Pulse with STAT's biotech reporting team., Raised roughly $6M total from Hearst Ventures, Correlation Ventures, Tuesday Capital, Boston Globe Media Partners, and STAT.

## Products & services

- **Predictive Intelligence Platform** — A real-time monitoring platform that mines clinical trial and biotech data, forecasting trial readouts and endpoints and issuing contextual alerts on delays, unexpected stops, enrollment changes, and status shifts across more than 100 risk categories.
- **STAT Trials Pulse** — A clinical-trials monitoring tool built with STAT that uses machine learning and editorial-driven algorithms to help life-sciences professionals prioritize the most important trial updates.
- **Clinical Trial API & Data Feeds** — Structured data feeds and an API delivering trial events, risk signals, and forecasts into customers' own systems and workflows.
- **Bloomberg Terminal Pharma News** — AI-powered, real-time pharma and biotech news signals delivered to financial professionals through the Bloomberg Terminal.

## Achievements

- Signals and AI-powered pharma news distributed through the Bloomberg Terminal.
- Co-created STAT Trials Pulse with STAT's biotech reporting team.
- Raised roughly $6M total from Hearst Ventures, Correlation Ventures, Tuesday Capital, Boston Globe Media Partners, and STAT.
- Collaborated with Bain & Company on quantifying biopharma execution risk.
- Spun out of the Newlab Venture Studio and founded by former WSJ and Associated Press computational journalists.

## Latest updates

- **2024-05** — Announced collaboration with Bloomberg to provide AI-powered, real-time pharma news on the Bloomberg Terminal.
- **2024** — Collaborated with Bain & Company on an AI approach to quantify biopharma execution risk in clinical trials.
- **2022-09** — Launched STAT Trials Pulse with STAT to anticipate roadblocks in clinical trials.
- **2022-03** — Raised $3.5M seed round led by Hearst Ventures to expand its event-detection platform.
- **2021-04** — Raised $1.5M to build 'editorial algorithms' that track real-time data.

## Links

- Website: https://appliedxl.com
- LinkedIn: https://www.linkedin.com/company/appliedxl
- Twitter/X: https://twitter.com/appliedxl

---

Profile page: https://yespress.io/appliedxl
Published by YesPress — https://yespress.io
Last updated: 2026-07-07